News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

AstraZeneca PLC (AZN) Takes On Merck & Co., Inc. (MRK) In Alzheimer's Drug Race


2/6/2014 7:45:03 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

AstraZeneca is moving an experimental Alzheimer's drug into late-stage development, taking on U.S. rival Merck & Co which announced plans to start similar final-stage research in December. Britain's second-biggest drugmaker revealed its plan to move AZD3293 into the last phase of testing needed for registration as it announced full-year results on Thursday. Both the AstraZeneca and Merck medicines work by blocking an enzyme called beta secretase that is involved in production of beta-amyloid, a protein that creates brain plaques considered a major cause of Alzheimer's disease.

Help employers find you! Check out all the jobs and post your resume.

Read at Reuters

comments powered by Disqus
Reuters
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES